A Bioanalytical Method Using High-performance Liquid Chromatography-mass Spectrometry for Determining Empagliflozin and Linagliptin in Human Plasma: Application in Bioequivalence Pharmacokinetic Study
Authors:
- 5 December 2024
- journal article
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (9) , 978-993
Abstract
Background and Objective: A combination of empagliflozin and linagliptin in a fixed dosage was employed for treating individuals with a diagnosis of type 2 diabetes mellitus. A rapid, accurate, and sensitive liquid chromatography-tandem mass spectrometry method was devised and validated for simultaneous measuring empagliflozin and linagliptin levels in human plasma. This method provides a good analytical tool for bioequivalence and pharmacokinetic studies. Methods: The separation was conducted employing a C8 column using a mobile phase consisting of acetonitrile (ACN, 2.5mM) and ammonium chloride (55:45). Optimal detection of the analytes and their deuterated internal standards was accomplished through electrospray ionization in the positive mode. Results: Validation of standard curve concentrations linearity was carried out within the ranges of 1.500 – 500.000 ng/mL for empagliflozin and 0.050 – 7.000 ng/mL for linagliptin. Both drugs showed intra-batch and inter-batch precision (CV%) of less than 3.7%. The stability of the drugs was confirmed under various storage conditions, proving suitability for routine laboratory analysis. Conclusion: This validated method is appropriate for pharmacokinetic studies and large-scale analysis with high precision and accuracy.Keywords
This publication has 19 references indexed in Scilit:
- Quantitation of thiorphan in human plasma using LC-MS/MS and its application to a bioequivalence studyJournal of Chromatography B, 2024
- Development and validation of an LC–MS/MS generic assay platform for small molecule drug bioanalysisJournal of Pharmaceutical and Biomedical Analysis, 2021
- Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasmaSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2021
- Mixed-mode solid phase extraction combined with LC-MS/MS for determination of empagliflozin and linagliptin in human plasmaMicrochemical Journal, 2019
- Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled TrialsAdvances in Therapy, 2018
- Sample preparation techniques for mass spectrometry in the clinical laboratory2017
- Advances in Clinical Mass Spectrometry2017
- Ion suppression; A critical review on causes, evaluation, prevention and applicationsTalanta, 2013
- Matrix effect marker for multianalyte analysis by LC–MS/MS in biological samplesJournal of Chromatography B, 2012
- Higher Throughput Bioanalysis by Automation of a Protein Precipitation Assay Using a 96-Well Format with Detection by LC−MS/MSAnalytical Chemistry, 2000